In the BioHarmony Drug Report Database
Telotristat etiprate
Xermelo (telotristat etiprate) is a small molecule pharmaceutical. Telotristat etiprate was first approved as Xermelo on 2017-02-28. It is used to treat diarrhea and malignant carcinoid syndrome in the USA. Xermelo’s patents are valid until 2031-02-27 (FDA).
Trade Name
|
Xermelo |
|---|---|
Common Name
|
telotristat etiprate |
ChEMBL ID
|
CHEMBL3348963 |
Indication
|
diarrhea, malignant carcinoid syndrome |
Drug Class
|
Enzyme inhibitors: tryptophan hydroxylase inhibitors |
Image (chem structure or protein)